肿瘤细胞治疗研究
ALL SOURCES
Intrinsic tumor cell line immunogenicity may drive CAR-independent T cell responses and confound CAR T cell preclinical modeling.
这些发现表明，某些肿瘤细胞系能够引发强烈的同种异体T细胞反应，且不依赖于CAR特异性，揭示了常用临床前模型的一个重要局限性，并凸显了CAR T细胞疗效评估中出现假阳性的可能性。
Engineering Interferon-γ-Enhanced Chimeric Antigen Receptor Macrophages via Lipid-Assisted Polymeric Nanoparticles for Cancer Immunotherapy.
目的 To develop an efficient strategy for in vivo engineering of M1-like CAR-Ms for cancer therapy. 方法 We designed a lentiviral vector encoding a CAR targeting BCMA and a cytokine cassette. Macrophages were transduced and
Identifying and reprogramming softness-driven cancer stem-like cells overcomes CAR-T cell resistance in solid tumours.
实体瘤表现出显著的力学异质性，但这力学线索如何影响癌细胞对 T 细胞疗法的敏感性仍不清楚。
Expansion and CAR engineering of granulocyte-monocyte progenitors for cellular immunotherapy.
这些发现确立了可扩增GMP作为工程化免疫治疗的可扩展平台。
A regenerative and programmable iPSC-derived platelet platform for universal drug delivery and immunotherapy.
基于血小板的药物递送系统在癌症治疗中日益受到关注，但其更广泛的应用受到来源有限和基因可修饰性差的制约。
Clickable Universal Tumor-Antigen Equipping Strategy for Remedial Chimeric Antigen Receptor T Cells to Destroy Solid Tumors.
嵌合抗原受体（CAR）-T细胞疗法在白血病和淋巴瘤中展现出显著疗效，但实体瘤仍大多难以治疗，原因在于肿瘤特异性抗原稀缺及广泛的抗原异质性，加之CAR-T细胞快速耗竭限制了其功能与持久性。
In vivo genome-wide CRISPR screens identify FOXR1 as a suppressor of CD8(+) T cell antitumor immunity.
T细胞功能障碍严重限制了实体瘤中基于T细胞的免疫疗法的疗效，然而T细胞功能障碍的内在调控因子仍未完全阐明。
In vivo generation of CAR myeloid cells through erythrocyte-mediated mRNA delivery for cancer immunotherapy.
我们的研究建立了一个可临床转化的基于红细胞的 mRNA 平台，该平台能够实现直接的体内免疫细胞编程，并推动了针对实体瘤的 CAR 髓系疗法的发展。
CDK4/6 inhibition enhances CAR-T cell therapy in solid tumors.
这些发现共同表明，曲拉西利和 CAR-T 细胞疗法可能是实体瘤的有效联合治疗。
A global multidimensional analysis of the chimeric antigen receptor T-cell therapy clinical trial landscape and development trends.
中国（1,006 项试验）和美国（549 项试验）占所有研究的 80% 以上。
MEMBER ACCOUNT
登录成功会直接打开下一页。
